{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T21:50:38Z","timestamp":1781733038263,"version":"3.54.5"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T00:00:00Z","timestamp":1591833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.00910","type":"journal-article","created":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T04:50:41Z","timestamp":1591851041000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["External Validation of a Predictive Model of Urethral Strictures for Prostate Patients Treated With HDR Brachytherapy Boost"],"prefix":"10.3389","volume":"10","author":[{"given":"Vanessa","family":"Panettieri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Rancati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Onjukka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin A.","family":"Ebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Denham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Steigler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy L.","family":"Millar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,6,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"323","DOI":"10.5114\/jcb.2014.45759","article-title":"High-dose-rate brachytherapy boost for prostate cancer: rationale and technique","volume":"6","author":"Morton","year":"2014","journal-title":"J Contemp Brachytherapy."},{"key":"B2","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.radonc.2014.10.007","article-title":"Dosimetric analysis of urethral strictures following HDR (192)Ir brachytherapy as monotherapy for intermediate- and high-risk prostate cancer","volume":"113","author":"Diez","year":"2014","journal-title":"Radiother Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.brachy.2019.01.013","article-title":"Improved survival for patients with prostate cancer receiving high-dose-rate brachytherapy boost to EBRT compared with EBRT alone","volume":"18","author":"Kent","year":"2019","journal-title":"Brachytherapy."},{"key":"B4","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/1754-9485.12699","article-title":"Under-utilisation of high-dose-rate brachytherapy boost in men with intermediate-high risk prostate cancer treated with external beam radiotherapy","volume":"62","author":"Ong","year":"2018","journal-title":"J Med Imaging Radiat Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.radonc.2012.01.007","article-title":"Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer","volume":"103","author":"Hoskin","year":"2012","journal-title":"Radiother Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.radonc.2019.08.017","article-title":"Results of 15Gy HDR-BT boost plus EBRT in intermediate-risk prostate cancer: analysis of over 500 patients","volume":"141","author":"Martell","year":"2019","journal-title":"Radiother Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.ijrobp.2009.10.035","article-title":"Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy","volume":"79","author":"Martinez","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S0360-3016(01)01607-8","article-title":"Is \u03b1\/\u03b2 for prostate tumors really low?","volume":"50","author":"Fowler","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"B9","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.semradonc.2019.08.003","article-title":"HDR prostate brachytherapy","volume":"30","author":"Crook","year":"2020","journal-title":"Semin Radiat Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.brachy.2012.03.004","article-title":"Urethral strictures following high-dose-rate brachytherapy for prostate cancer: analysis of risk factors","volume":"12","author":"Hindson","year":"2013","journal-title":"Brachytherapy."},{"key":"B11","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/bju.13659","article-title":"Long-term outcomes of high-dose-rate brachytherapy for intermediate- and high-risk prostate cancer with a median follow-up of 10 years","volume":"120","author":"Yaxley","year":"2017","journal-title":"BJU Int."},{"key":"B12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ijrobp.2008.11.006","article-title":"Genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with Hypofractionated External beam radiotherapy for localized prostate cancer: an analysis to determine the correlation between dose-volume histogram parameters in HDR brachytherapy and severity of toxicity","volume":"75","author":"Ishiyama","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"B13","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.brachy.2015.04.004","article-title":"High-dose-rate brachytherapy boost for prostate cancer: outcomes and genitourinary toxicity","volume":"14","author":"Bece","year":"2015","journal-title":"Brachytherapy."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/j.ijrobp.2011.04.031","article-title":"High-dose-rate brachytherapy alone for localized prostate cancer in patients at moderate or high risk of biochemical recurrence","volume":"82","author":"Hoskin","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"B15","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.radonc.2013.05.002","article-title":"GEC\/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update","volume":"107","author":"Hoskin","year":"2013","journal-title":"Radiother Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.brachy.2011.09.008","article-title":"American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy","volume":"11","author":"Yamada","year":"2012","journal-title":"Brachytherapy."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1016\/j.ijrobp.2018.08.015","article-title":"A Systematic post-QUANTEC review of tolerance doses for late toxicity after prostate cancer radiation therapy","volume":"102","author":"Olsson","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"B18","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.ijrobp.2019.01.088","article-title":"Voxel-based analysis for identification of urethrovesical subregions predicting urinary toxicity after prostate cancer radiation therapy","volume":"104","author":"Mylona","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"B19","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.ijrobp.2016.10.024","article-title":"Modeling urinary dysfunction after external beam radiation therapy of the prostate using bladder dose-surface maps: evidence of spatially variable response of the bladder surface","volume":"97","author":"Yahya","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"B20","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.radonc.2014.02.006","article-title":"Relationships between bladder dose-volume\/surface histograms and acute urinary toxicity after radiotherapy for prostate cancer","volume":"111","author":"Carillo","year":"2014","journal-title":"Radiother Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"5126","DOI":"10.1118\/1.3481514","article-title":"Assessment of normal tissue complications following prostate cancer irradiation: comparison of radiation treatment modalities using NTCP models","volume":"37","author":"Takam","year":"2010","journal-title":"Med Phys."},{"key":"B22","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1120\/jacmp.v14i1.3882","article-title":"Dosimetric assessment of prostate cancer patients through principal component analysis (PCA)","volume":"14","author":"Gloi","year":"2013","journal-title":"J Appl Clin Med Phys."},{"key":"B23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.brachy.2009.04.007","article-title":"High-dose-rate brachytherapy in combination with conformal external beam radiotherapy in the treatment of prostate cancer","volume":"9","author":"Zwahlen","year":"2010","journal-title":"Brachytherapy."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.urology.2010.01.027","article-title":"Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors","volume":"76","author":"Szymanski","year":"2010","journal-title":"Urology."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/0360-3016(89)90972-3","article-title":"Calculation of complication probability factors for non-uniform normal tissue irradiation: the effective volume method gerald","volume":"16","author":"Kutcher","year":"1989","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"B26","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.2307\/3576626","article-title":"Complication probability as assessed from dose-volume histograms","volume":"104","author":"Lyman","year":"1985","journal-title":"Radiat Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1118\/1.4917219","article-title":"The performance of normal-tissue complication probability models in the presence of confounding factors","volume":"42","author":"Onjukka","year":"2015","journal-title":"Med Phys."},{"key":"B28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.radonc.2004.08.013","article-title":"Fitting late rectal bleeding data using different NTCP models: results from an Italian multi-centric study (AIROPROS0101)","volume":"73","author":"Rancati","year":"2004","journal-title":"Radiother Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.ijrobp.2005.11.022","article-title":"Multivariable modeling of radiotherapy outcomes, including dose-volume and clinical factors","volume":"64","author":"El Naqa","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B30","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.radonc.2015.11.036","article-title":"Multi-variable models of large International Prostate Symptom Score worsening at the end of therapy in prostate cancer radiotherapy","volume":"118","author":"Palorini","year":"2016","journal-title":"Radiother Oncol."},{"key":"B31","volume-title":"Clinical Prediction Models A Practical Approach to Development, Validation, and Updating","author":"Steyerberg","year":"2009"},{"key":"B32","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.radonc.2015.05.016","article-title":"Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial","volume":"115","author":"Denham","year":"2015","journal-title":"Radiother Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ijrobp.2006.03.034","article-title":"Rectal bleeding, fecal incontinence, and high stool frequency after conformal radiotherapy for prostate cancer: normal tissue complication probability modeling","volume":"66","author":"Peeters","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"B34","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.prro.2015.02.010","article-title":"Increased radiation dose heterogeneity within the prostate predisposes to urethral strictures in patients receiving moderately hypofractionated prostate radiation therapy","volume":"5","author":"McDonald","year":"2015","journal-title":"Pract Radiat Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.ijrobp.2007.04.049","article-title":"Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma","volume":"69","author":"Martin","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"B37","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ijrobp.2010.10.009","article-title":"Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer","volume":"82","author":"Mohammed","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"B38","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.radonc.2008.11.013","article-title":"Urethral stricture following high dose rate brachytherapy for prostate cancer","volume":"91","author":"Sullivan","year":"2009","journal-title":"Radiother Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.ijrobp.2009.08.048","article-title":"Phase II trial of combined high-dose-rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate: preliminary results of RTOG 0321","volume":"78","author":"Hsu","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.ijrobp.2008.12.051","article-title":"Correlation between dosimetric parameters and late rectal and urinary toxicities in patients treated with high-dose-rate brachytherapy used as monotherapy for prostate cancer","volume":"75","author":"Konishi","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"B41","doi-asserted-by":"publisher","first-page":"20190760","DOI":"10.1259\/bjr.20190760","article-title":"A pilot study on dosimetric and radiomics analysis of urethral strictures following HDR brachytherapy as monotherapy for localized prostate cancer","volume":"93","author":"Tsang","year":"2019","journal-title":"Br J Radiol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.radonc.2016.05.010","article-title":"Independent external validation of predictive models for urinary dysfunction following external beam radiotherapy of the prostate: issues in model development and reporting","volume":"120","author":"Yahya","year":"2016","journal-title":"Radiother Oncol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"309","DOI":"10.4111\/icu.2016.57.5.309","article-title":"Urethral strictures after radiation therapy for prostate cancer","volume":"57","author":"Moltzahn","year":"2016","journal-title":"Investig Clin Urol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1080\/0284186X.2018.1433874","article-title":"Clinical estimation of \u03b1\/\u03b2 values for prostate cancer from isoeffective phase III randomized trials with moderately hypofractionated radiotherapy","volume":"57","author":"Datta","year":"2018","journal-title":"Acta Oncol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.brachy.2017.08.004","article-title":"An integrated system for clinical treatment verification of HDR prostate brachytherapy combining source tracking with pretreatment imaging","volume":"17","author":"Smith","year":"2018","journal-title":"Brachytherapy."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00910\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T04:50:43Z","timestamp":1591851043000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00910\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,11]]},"references-count":45,"alternative-id":["10.3389\/fonc.2020.00910"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.00910","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,11]]},"article-number":"910"}}